Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Bite Stories

2009-06-02 06:00:00

BETHESDA, Md., June 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a webcast on June 8, 2009 to discuss the blinatumomab data presented on June 5th and 6th at the 14th Congress of the European Hematology Association. The webcast will be available on the company's website at www.micromet-inc.com. Forum:...

2009-06-01 06:00:00

Data indicate target-dependent activity in breast cancer patients with high expression of EpCAM ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented data from a clinical trial investigating its anti-EpCAM human antibody adecatumumab (MT201) in combination with the chemotherapeutic docetaxel in patients with metastatic...

2009-05-20 06:00:00

Activity of Blinatumomab in NHL and ALL Highlighted at the 14th Congress of the European Hematology Association (EHA) Adecatumumab Combination Data in Breast Cancer to Be Presented at the American Society of Clinical Oncology (ASCO) Meeting BETHESDA, Md., May 20 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced an oral(1) and a poster...

ac5a1edd09a20aeeb091285da1d82a0a1
2009-05-19 13:44:50

Australian researchers have discovered what makes the Komodo dragon's bite so deadly for its prey. Scientists previously considered that the world's largest lizard's mouth held deadly bacteria that stopped its victims' blood from clotting. Walter Auffenberg put that theory forward in 1981. But lead researcher Bryan Fry used magnetic resonance imagery to show that the deadly lizard packs a venomous bite, as seen through its venom gland with ducts that lead to their teeth. Fry used 3-D computer...

2009-05-06 06:00:00

BETHESDA, Md., May 6 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2009. In the first quarter of 2009, Micromet achieved a number of significant milestones illustrating its continued progress in the clinic and in corporate development. The milestones include the execution...

2009-04-30 06:00:00

BETHESDA, Md., April 30 /PRNewswire/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a conference call and audio webcast on Wednesday, May 6, 2009, at 9:00 am Eastern Time (3:00 pm Central European Time) to discuss its financial results for the first quarter of 2009. Micromet anticipates releasing its financial results at 7:00 am...

2009-04-28 05:00:00

OSLO, Norway, April 28 /PRNewswire/ -- Affitech AS, the human antibody therapeutics company, announced today that preclinical data on two fully human anti-PS (phosphatidylserine) antibodies were presented by its collaboration partner Peregrine Pharmaceuticals at the 100th Annual Meeting of the American Association for Cancer Research (AACR) 2009 held during April 18 - 22, 2009 in Denver, CO. The preclinical studies of PGN635 and PGN632 provided further confirmatory evidence that the...

2009-04-24 09:30:00

Pivotal Trial Expected to Initiate in 2010 for Blinatumomab NEW YORK, April 24 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today held an R&D Day for investors and financial analysts at The Yale Club of New York City. The presentations highlighted significant areas of development across Micromet's BiTE antibody platform and included...

2009-04-22 09:00:00

-Preclinical Results Further Validate Significant Anti-Tumor Potential of Fully Human Anti-PS Antibodies and Expand the Company's PS-Targeting Platform- -Treatment with Mouse Equivalent to the Human Antibody Inhibited Tumor Growth in a Prostate Cancer Model by More than 90%- DENVER and TUSTIN, Calif., April 22 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer...

2009-04-22 06:00:00

Study Presented at 2009 AACR Meeting Highlights Potential Therapeutic Approach to Treat Patients Unresponsive to Erbitux and Vectibix DENVER, April 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, yesterday presented non-clinical data at the annual meeting of the American Association for Cancer Research (AACR). These non-clinical data indicate...


Latest Bite Reference Libraries

0_e288c9a7e7e932afbeba3516c20e64f2
2009-06-16 22:38:30

The Brown Recluse Spider (Loxosceles reclusa) is a species of arachnid that is native to the USA from the southern Midwest south to the Gulf of Mexico. It can be found in Canada as well around southeast Ontario, and southern Quebec. Its range lies from southeastern Nebraska through southern Iowa, Illinois, and Indiana to southwestern Ohio. In the south, it is native from central Texas to western Georgia. It is not usually found west of the Rocky Mountains. Contrary to popular belief, this...

More Articles (1 articles) »